20 results on '"Tonali, Pietro"'
Search Results
2. Breastfeeding and multiple sclerosis.
- Author
-
Iorio R, Nociti V, Frisullo G, Patanella AK, Tonali PA, and Batocchi AP
- Subjects
- Adult, Female, Humans, Multiple Sclerosis prevention & control, Breast Feeding, Multiple Sclerosis physiopathology
- Published
- 2009
- Full Text
- View/download PDF
3. Glioblastoma in multiple sclerosis: a case report.
- Author
-
Frisullo G, Patanella AK, Nociti V, Cianfoni A, Iorio R, Bianco A, Marti A, Tonali PA, and Batocchi AP
- Subjects
- Brain Neoplasms immunology, Brain Neoplasms pathology, Glioblastoma immunology, Glioblastoma pathology, Humans, Magnetic Resonance Imaging methods, Male, Middle Aged, Multiple Sclerosis immunology, Multiple Sclerosis pathology, STAT1 Transcription Factor, STAT3 Transcription Factor metabolism, T-Lymphocytes, Regulatory, Brain Neoplasms complications, Glioblastoma complications, Multiple Sclerosis complications
- Abstract
Cerebral tumor and multiple sclerosis (MS) relapses can show overlapping clinical and magnetic resonance imaging features. In a previous study we observed in relapsing MS patients increased T-bet, pSTAT1, and pSTAT3 expressions in circulating mononuclear cells. During the data analysis we observed that T-bet, pSTAT1, and pSTAT3 expression was not increased in circulating mononuclear cells from a relapsing-remitting (RR)MS patient with recent onset of new neurological signs due to glioblastoma multiforme. In conclusion, our patient represents an exemplary case which suggests that T-bet, pSTAT1, and pSTAT3 expression in peripheral blood mononuclear cells (PBMCs) might be useful to differentiate MS relapses from other noninflammatory diseases.
- Published
- 2009
- Full Text
- View/download PDF
4. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis.
- Author
-
Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Mirabella M, Tonali PA, and Batocchi AP
- Subjects
- Adult, Case-Control Studies, Cytokines metabolism, Disease Progression, Female, Humans, Male, Young Adult, CD4-Positive T-Lymphocytes metabolism, Multiple Sclerosis blood, Multiple Sclerosis immunology, STAT3 Transcription Factor metabolism
- Abstract
Not all patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) develop clinically defined MS (CDMS). At first clinical event we observed increased production of IL17, IFNgamma and IL10 by peripheral blood mononuclear cells from patients with CIS that remained high in remission. In CD4+ T cells pSTAT3 expression was higher in patients who subsequently converted to CDMS than in patients who did not and controls. The persistency of high levels of pSTAT3 in circulating CD4+ T cells from CIS patients after the first clinical event may favor the early conversion to CDMS.
- Published
- 2008
- Full Text
- View/download PDF
5. Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease.
- Author
-
Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Cammarota G, Mirabella M, Attilio Tonali P, and Batocchi AP
- Subjects
- Adult, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Celiac Disease blood, Celiac Disease complications, Celiac Disease physiopathology, Diet, Gluten-Free, Disease Progression, Female, Headache, Humans, Hypesthesia, Infant, Newborn, Interferon-gamma metabolism, Lymphocyte Activation, Male, Methylprednisolone administration & dosage, Monocytes immunology, Multiple Sclerosis blood, Multiple Sclerosis complications, Multiple Sclerosis physiopathology, Pregnancy, Pregnancy Complications blood, Pregnancy Complications immunology, Pregnancy Complications physiopathology, Receptors, Fc blood, Recovery of Function, Remission, Spontaneous, T-Box Domain Proteins genetics, Transcriptional Activation, Transglutaminases immunology, B-Lymphocytes metabolism, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes metabolism, Celiac Disease immunology, Monocytes metabolism, Multiple Sclerosis immunology, T-Box Domain Proteins blood
- Abstract
Multiple sclerosis (MS) and celiac disease (CD) are considered to be T-cell-mediated autoimmune diseases. We describe a woman affected by a relapsing-remitting demyelinating disease of the central nervous system and occult CD (MS-CD), who showed during neurologic exacerbations a strong increased expression of T-bet, the key transcription factor for the development of Th1 cells, in circulating T, B cells and monocytes. Conversely, no difference of T-bet expression was observed in B cells from relapsing-remitting MS patients, either in relapse or in remission, and in controls. In the MS-CD patient, the interaction between MS- and CD-related inflammatory processes may result in an amplification of Th1 immune response.
- Published
- 2008
- Full Text
- View/download PDF
6. Somatosensory evoked potentials reflect the upper limb motor performance in multiple sclerosis.
- Author
-
Nociti V, Batocchi AP, Bartalini S, Caggiula M, Patti F, Profice P, Quattrone A, Tonali P, Ulivelli M, Valentino P, Virdis D, Zappia M, and Padua L
- Subjects
- Adult, Electroencephalography methods, Female, Humans, Male, Median Nerve physiopathology, Median Nerve radiation effects, Mental Status Schedule, Middle Aged, Retrospective Studies, Somatosensory Cortex physiopathology, Statistics, Nonparametric, Surveys and Questionnaires, Upper Extremity physiopathology, Evoked Potentials, Somatosensory physiology, Multiple Sclerosis pathology, Psychomotor Performance physiology, Somatosensory Cortex pathology, Upper Extremity pathology
- Abstract
Objective: The aim of this multicentric study was to multidimensionally evaluate the relationship among somatosensory evoked potentials (SEPs) parameters, patient's perspective and clinical measures of the upper limb impairment in patients with multiple sclerosis (MS)., Methods: We consecutively enrolled 39 MS patients. For median nerve SEPs we acquired the N9, P14, N20 responses and the N9-P14 and P14-N20 interpeak latencies on the dominant side. We also used a validated patient-oriented questionnaire (Disabilities of the Arm, Shoulder and Hand - DASH) and a test of dexterity quantification as the 9-Hole Peg Test (9-HPT)., Results: A significant longer time to complete the 9-HPT (p<0.00006) was observed in patients with abnormal SEPs. Patients with undetectable N20 or P14 responses performed the 9-HPT in a significant longer time than patients with detectable responses (p<0.0006 and p<0.001 respectively). Concerning the perspective of patient (evaluated with the DASH questionnaire) significant differences in patients with undetectable P14 response (p<0.01) were observed., Conclusions: Our data provide further information useful for interpretation of SEPs results, being the median nerve SEPs related to the upper limb performance in MS patients., Significance: These data increase the significance of SEPs both in clinical practice and in experimental studies in MS.
- Published
- 2008
- Full Text
- View/download PDF
7. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
- Author
-
Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, and Batocchi AP
- Subjects
- Adult, Demyelinating Diseases blood, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive blood, Multiple Sclerosis, Relapsing-Remitting blood, Interferon-gamma biosynthesis, Interleukin-10 biosynthesis, Interleukin-17 biosynthesis, Leukocytes, Mononuclear metabolism, Multiple Sclerosis blood
- Abstract
We evaluated the spontaneous IL17, IFNgamma and IL10 production by peripheral blood mononuclear cells from patients affected by clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) both in acute phase and in remission, relapsing remitting MS (RRMS) both in relapse and in remission, not-relapsing secondary progressive MS (SPMS) and controls. We observed higher IL17 levels in CIS patients both in acute phase and in remission than in SPMS patients and controls. On the contrary no difference in IL17 production was observed among RRMS patients and CIS, SPMS patients and controls. IFNgamma levels were significantly higher in CIS patients in acute phase than in CIS and RRMS patients in remission, SPMS patients and controls. Moreover, we observed higher IFNgamma spontaneous production in relapsing RRMS patients than in remitting RRMS and SPMS patients and controls. IL10 levels were significantly higher in remitting CIS and in relapsing RRMS patients than in SPMS patients and controls. There was no difference in IFNgamma, IL10 and IL17 levels between SPMS patients and controls. Our data suggest that IL17 might play a crucial role mainly in the early phase of MS, while IFNgamma seems to be involved both in the early phase and in the following relapses of the disease.
- Published
- 2008
- Full Text
- View/download PDF
8. Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy.
- Author
-
Angelucci F, Mirabella M, Frisullo G, Caggiula M, Tonali PA, and Batocchi AP
- Subjects
- Adult, Amino Acid Sequence, Female, Humans, Interferon-beta therapeutic use, Male, Molecular Sequence Data, Multiple Sclerosis therapy, Myelin Basic Protein immunology, Myelin Proteins, Myelin-Oligodendrocyte Glycoprotein, Autoantibodies blood, Multiple Sclerosis immunology, Myelin-Associated Glycoprotein immunology
- Abstract
Antibodies against myelin oligodendrocyte antigens have been found in the immunoreactive brain lesions of Multiple Sclerosis (MS) patients. Recently it has been proposed that these antibodies can be used as a prognostic marker in the course of disease. However, the serum levels of these autoantibodies during different phases of disease activity or after an immunomodulatory therapy have been poorly investigated. In this study the serum levels of anti-myelin oligodendrocyte glycoprotein (MOG) (directed against the epitopes 1-26 and 15-40) and anti-myelin basic protein (MBP) antibodies were sequentially measured in the same MS patient either in relapse or remission phases. We found that MS patients in the relapse phase had higher serum anti-MOG (peptides 1-26 and 15-40) and anti-MBP antibody levels than controls. In addition, the levels of anti-MOG 1-26 were also elevated during the relapse as compared with the remission phase but no significant changes were found in the levels of anti-MOG 15-40 of anti-MBP antibodies. We also evaluated the effect of interferon-beta (beta) therapy on anti-myelin antibodies. 1-year of interferon-beta treatment did not induce any changes in the levels of anti-MOG and anti-MBP antibodies. In conclusion, these data indicate that the use of peripheral levels of autoantibodies against MOG and MBP as marker of multiple sclerosis might be complicated by the phase of disease activity and by the epitope of the MOG protein used.
- Published
- 2005
- Full Text
- View/download PDF
9. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta.
- Author
-
Batocchi AP, Rotondi M, Caggiula M, Frisullo G, Odoardi F, Nociti V, Carella C, Tonali PA, and Mirabella M
- Subjects
- Adult, Biomarkers blood, Cytokines biosynthesis, Cytokines metabolism, Female, Humans, Interferon beta-1a, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Male, Middle Aged, Multiple Sclerosis physiopathology, Reference Values, Secondary Prevention, Treatment Outcome, Interferon-beta pharmacology, Interferon-beta therapeutic use, Leptin blood, Multiple Sclerosis blood, Multiple Sclerosis drug therapy
- Abstract
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.
- Published
- 2003
- Full Text
- View/download PDF
10. Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients
- Author
-
Frisullo, Giovanni, Angelucci, Francesco, Mirabella, Massimiliano, Caggiula, Marcella, Patanella, Katia, Nociti, Viviana, Tonali, Pietro Attilio, and Batocchi, Anna Paola
- Published
- 2004
- Full Text
- View/download PDF
11. Regulatory T cells fail to suppress CD4(+)T-bet(+) T cells in relapsing multiple sclerosis patients
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Patanella, Agata Katia, Caggiula, Marcella, Marti, Alessandro, Sancricca, Cristina, Mirabella, Massimiliano, Tonali, Pietro Attilio, and Batocchi, Anna Paola
- Subjects
regulatory T cell ,Settore MED/26 - NEUROLOGIA ,multiple sclerosis - Published
- 2008
12. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Patanella, Agata Katia, Marti, Alessandro, Caggiula, Marcella, Mirabella, Massimiliano, Tonali, Pietro Attilio, and Batocchi, Anna Paola
- Subjects
Settore MED/26 - NEUROLOGIA ,IL17 ,cytokine ,multiple sclerosis ,IFN - Published
- 2008
13. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients
- Author
-
Padua, Luca, Nociti, Viviana, Bartalini, Sabina, Patti, Francesco, Quattrone, Aldo, Tonali, Pietro Attilio, Ulivelli, Monica, Valentino, Paola, Zappia, Mauro, and Batocchi, Anna Paola
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Paced Auditory Serial Addition Test ,Cross-sectional study ,Neuropsychological Tests ,Central nervous system disease ,Upper Extremity ,Disability Evaluation ,Cognition ,Quality of life ,medicine ,Outpatient clinic ,Humans ,Motor assessment ,Fatigue ,Aged ,Sclerosis ,medicine.diagnostic_test ,Multiple sclerosis ,Middle Aged ,medicine.disease ,Settore MED/26 - NEUROLOGIA ,Cross-Sectional Studies ,Neurology ,Physical therapy ,Quality of Life ,Female ,Neurology (clinical) ,Psychology - Abstract
The aim of this study was to assess the motor function of upper extremity and its relation with fatigue, cognitive function and quality of life in Multiple Sclerosis (MS) patients.Cross-sectional and controlled study.Outpatient clinic in a university hospital.Thirty-one patients with MS (25 women, 6 men; mean age 39.74 +/- 10.10 years; mean EDSS, 2.56 +/- 1.91) and 30 healthy subjects (20 women, 10 men; mean age 33.56 +/- 8.85 years) were enrolled into the study.Nine-hole peg test (9-HPT) and Valpar Component Work Sample Test (VCWS-4), Upper Extremity Index (UEI), Paced Auditory Serial Addition Test (PASAT), Fatigue Severity Scale (FSS), and the Multiple Sclerosis Quality of Life-54 (MSQOL-54).MS patients showed significant impairment in upper extremity motor functions, cognitive function and excessive fatigue compared to controls (p0.05). 9-HPT in MS group correlated with EDSS, UEI and MSQOL-54 physical health and cognitive function, whereas VCWS-4 scores (assembly right, assembly left and disassembly) correlated only with EDSS and UEI. No correlation was found between the VCWS-4 and cognitive function and fatigue in both of the groups. Compared to control group, a strong correlation existed between the 9-HPT and VCWS-4 in MS patients (p0.05).The results indicate that disability level (EDSS), UEI and cognitive function in MS patients are related with impairment in upper extremity motor function. This again contributes to an impairment in physical domain of quality of life. A strong correlation of the 9-HPT with VCWS-4 supports the use of the 9-HPT as a measure of manual dexterity and gross motor functions.
- Published
- 2005
14. Regulatory T cells fail to suppress CD4+ T-bet+ T cells in relapsing multiple sclerosis patients.
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Patanella, Agata K., Caggiula, Marcella, Marti, Alessandro, Sancricca, Cristina, Angelucci, Francesco, Mirabella, Massimiliano, Tonali, Pietro A., and Batocchi, Anna P.
- Subjects
T cells ,CD4 antigen ,MULTIPLE sclerosis ,DISEASE relapse ,DISEASE remission ,PATIENTS - Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system and a defect in the regulatory T-cell subset seems to be involved in the pathogenesis of the disease. Foxp3 is a transcription factor that is selectively expressed in CD4
+ CD25+ regulatory T cells and is required for their development and function. T-bet is a key transcription factor for the development of T helper 1 (Th1) cells. We found that both the percentage of circulating CD4+ CD25+ Foxp3+ cells and Foxp3 expression were lower in relapsing-remitting (RR) MS patients during relapses than during remission. Otherwise, the percentage of CD4+ T-bet+ T cells and T-bet expression in CD4+ T cells were higher in relapsing than in remitting RRMS patients. CD4+ CD25+ T cells both from relapsing and from remitting RRMS patients showed significantly less capacity than corresponding cells from healthy subjects to suppress autologous CD4+ CD25− T-cell proliferation, despite a similar Foxp3 expression level. CD4+ CD25+ T cells from healthy subjects and patients in remission clearly reduced T-bet mean fluorescence intensity (MFI) in CD4+ CD25− T cells up to a ratio of 1:10, whereas CD4+ CD25+ T cells from patients in relapse were able to reduce T-bet expression only at a high ratio. Our data indicate that the increased number of regulatory T (T-reg) cells and the increased Foxp3 expression in circulating CD4+ CD25+ T cells may contribute to the maintenance of tolerance in the remission phase of MS. Moreover, the inhibitory capacity of CD4+ CD25+ T cells seems to be impaired in relapsing patients under inflammatory conditions, as shown by the high levels of T-bet expression in CD4+ T cells. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
15. CD8+Foxp3+ T cells in peripheral blood of relapsing-remitting multiple sclerosis patients
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Plantone, Domenico, Patanella, A. Katia, Tonali, Pietro A., and Batocchi, Anna Paola
- Subjects
- *
T cells , *BLOOD vessels , *IMMUNE response , *FORKHEAD transcription factors , *GENE expression , *CYTOMETRY , *RELAPSING fever ,MULTIPLE sclerosis research - Abstract
Abstract: A defect of CD4+ regulatory T cells (Treg) seems to be involved in the pathogenesis of multiple sclerosis (MS). Besides Treg, CD8+ T cells also can suppress the immune response. Forkhead box p3 (Foxp3) is known to program the acquisition of suppressive capacities in CD4+ T cells and recent studies showed that in vitro antigen activation leads to Foxp3 expression in CD8+ T cells, gaining of suppressive activity. By flow cytometry we found a lower percentage of circulating CD8+Foxp3+ T cells in relapsing than in remitting patients with MS and in controls. No significant differences were observed in CD8+Foxp3+ T cell percentage between healthy subjects and patients in remission. Our data suggest that peripheral CD8+Foxp3+ T cells may play a role in the maintenance of tolerance in MS. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
16. Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Patanella, Agata Katia, Marti, Alessandro, Assunta, Bianco, Plantone, Domenico, Cammarota, Giovanni, Tonali, Pietro Attilio, and Batocchi, Anna Paola
- Subjects
- *
T cells , *LYMPHOCYTES , *MALABSORPTION syndromes , *CANCER patients - Abstract
Abstract: Regulatory CD4+ CD25+Foxp3+ T cells are involved in the regulation of immune response and inhibit protective antitumor immunity. Celiac disease (CD), a food gluten–sensitive enteropathy, is considered a T-cell–mediated autoimmune disease and is generally associated with an overall increased risk of cancer in CD patients. We observed a higher percentage of circulating CD4+CD25+Foxp3+ T cells and an increased Foxp3 expression in CD4+CD25+ T cells from untreated than from treated CD patients. In co-culture, CD4+CD25+ T cells from both treated and untreated CD patients significantly suppressed the proliferation of autologous CD4+CD25− T cells similarly to values in healthy subjects. Our study suggests that Treg proportion and Foxp3 expression in circulating CD4+CD25+ T cells could justify the increased global risk of malignancy in CD population and support the efficacy of lifelong gluten-free diet in the reduction of the cancer risk. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
17. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis
- Author
-
Frisullo, Giovanni, Mirabella, Massimiliano, Angelucci, Francesco, Caggiula, Marcella, Morosetti, Roberta, Sancricca, Cristina, Patanella, Agata Katia, Nociti, Viviana, Iorio, Raffaele, Bianco, Assunta, Tomassini, Valentina, Pozzilli, Carlo, Tonali, Pietro Attilio, Matarese, Giuseppe, and Batocchi, Anna Paola
- Subjects
- *
LEPTIN , *CYTOKINES , *MULTIPLE sclerosis , *DISEASE relapse - Abstract
Abstract: In this study we observed higher serum leptin levels in relapsing–remitting multiple sclerosis (RRMS) patients during remission than in controls. The expression of leptin receptor (ObR) was higher in CD8+ T cells and monocytes from RRMS patients in relapse than in patients in remission and in controls. Relapsing patients showed high levels of pSTAT3 and low expression of SOCS3 and leptin administration induced an up-regulation of pSTAT3 only in monocytes from patients in relapse. Our data suggest that ObR may be involved in the development of clinical relapses in RRMS patients and suggest a rationale for potential targeting of the leptin axis during MS. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
18. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients
- Author
-
Frisullo, Giovanni, Nociti, Viviana, Iorio, Raffaele, Katia Patanella, Agata, Bianco, Assunta, Caggiula, Marcella, Sancricca, Cristina, Tonali, Pietro Attilio, Mirabella, Massimiliano, and Batocchi, Anna Paola
- Subjects
- *
ADRENOCORTICAL hormones , *HORMONE therapy , *CLINICAL immunology , *MEDICAL sciences - Abstract
Abstract: High dose glucocorticoid (GC) treatment has been demonstrated to have a short-term beneficial effect on functional recovery in relapsing multiple sclerosis (MS) patients but the exact mechanism of action of GCs in MS is unclear. We found that high dose intravenous GCs strongly reduced T-bet and pSTAT1 expression in CD4+, CD8+, CD14+ circulating cells in RRMS patients in relapse. pSTAT1and T-bet reduction was associated with the decline of IFNγ production by PBMCs. A significant increase of AV-positive CD4+ and CD8+ T cells was detectable after GC treatment without any variation in the percentage of annexin V-positive monocytes. By in vitro analysis, patients during relapse, either before or after GC treatment, exhibited a lower proportion of apoptotic lymphocytes than remitting patients and controls. Our study suggests that GCs can modulate T-bet and STAT1 expression and that IFNγ signalling inhibition contributes to anti-inflammatory action of GCs in the treatment of relapses of MS patients. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
19. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
- Author
-
Caggiula, Marcella, Batocchi, Anna Paola, Frisullo, Giovanni, Angelucci, Francesco, Patanella, Agata Katia, Sancricca, Cristina, Nociti, Viviana, Tonali, Pietro Attilio, and Mirabella, Massimiliano
- Subjects
- *
ANTIVIRAL agents , *MULTIPLE sclerosis , *VIRUS diseases , *NERVE tissue proteins - Abstract
Abstract: Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing–remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
20. Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis
- Author
-
Angelucci, Francesco, Mirabella, Massimiliano, Caggiula, Marcella, Frisullo, Giovanni, Patanella, Katia, Sancricca, Cristina, Nociti, Viviana, Tonali, Pietro Attilio, and Batocchi, Anna Paola
- Subjects
- *
LEPTIN , *HORMONES , *MULTIPLE sclerosis , *DEMYELINATION - Abstract
Abstract: Leptin is a peptide hormone which acts on cells of immune system by influencing the production of cytokines. Serum leptin levels and cytokine production by peripheral blood mononuclear cells (PBMC) were measured in 18 secondary progressive multiple sclerosis (SPMS) patients under IFN-beta-1b treatment. There were no overall effects on leptin, interleukin-6 (IL-6), IL-10 and IL-12 p40 after 2, 6 and 12 months of treatment. However, leptin and IL-6 decreased after 6 and 12 months of treatment in 12 patients who did not show progression of disability. Thus, our pilot data show that the beneficial effect of IFN-beta on some SPMS patients might be associated with the reduced levels of leptin and reduced IL-6 production by PBMC. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.